empagliflozin semaglutide Glycaemic efficacy of oral versus empagliflozin. Results The Role of GLP-1, DPP-4,

A clinician-guided Care Plan that combines proven medications, hormone support when appropriate, and lifestyle strategies tailored to your body can deliver real results

However, it does not alter global methylation levels as measured by LINE-1 (Link et al., 2013)

Together, these findings highlight that although GLP-1 use may shift habits, it does not diminish the importance of restaurants in users routines

Conclusions Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events

However, a recent meta-analysis of all current CVOTs, showed that GLP-1RAs as a group were associated with a (non-significant) reduction in HF (104)